The pharmaceutical industry has recently witnessed quite a surge in research and development (R&D) costs.
A recent research records more than $1.23 trillion in sales in 2020 by the pharma industry, with about 46% of sales coming from North America.
This is a staggering figure which encompasses the direct costs of research, factoring in the lengthy timelines it requires and high failure rates associated with drug development.
It is also entirely possible that the cure for a rare disease may possibly not come from a $10 billion big pharma facility. It could easily be developed by a small, underdog startup with a brilliant idea but perhaps not the capital to develop it.
As a growing startup, as impossible as it may sound, navigating this landscape may not be completely insurmountable.
There are innovative strategies and technology that can be leveraged which can help pharma startups remain competitive while managing R&D expenses effectively.
The Rising Tide of R&D Costs
The startling problem with pharmaceutical R&D is how notoriously expensive and time-consuming they are.
Clinical trials, for instance, can take up to 10 or 15 years, with only 12% of drug candidates who successfully make it from Phase I to approval.
This is also after spending more than $2.6 billion to bring a new medicine to the market.
One would assume that an FDA approval might be where the innovation ends. Unfortunately, approved products still go through continuous development, learning, and reworking for improved efficiency.
Furthermore, intricate regulations make it more and more difficult to develop innovative medical products.
The higher cost of releasing a brand-new medicine onto the market only adds to the complications.
Contributing Factors Influencing R&D Spending
To determine the amount of money that drug companies devote to R&D, it is important to consider the amount of revenue they expect to earn from a new drug.
It also considers the expected cost of developing that specific drug and the policies that influence the supply of and demand for the same.
Global Revenue Potential
The projected global lifetime revenue of a new drug is largely influenced by the prices pharmaceutical companies plan to set across various international markets.
The estimated sales volume at those prices and the probability of successful drug development also contribute to the same.
Estimate the Cost of Developing the Drug
Capital investments and spending on unsuccessful candidates can be considered under the anticipated cost of developing a new drug.
This has been estimated to range between $1 billion and $2 billion.
Federal Policies
The federal government impacts private R&D spending by implementing programs like Medicare that boost demand for prescription drugs.
Policies that fund basic research or set clinical trial requirements affect the supply of new drugs. Other policies, such as vaccine recommendations, impact both supply and demand.
Navigating the Competitive Landscape
There are certain therapeutic areas that usually attract greater attention from the top players in the field, especially with pharmaceutical companies race to develop their next breakthrough.
When multiples pharma giants pour in their R&D efforts on the same indications, there are many implications that follow for startups that are looking to leverage their playground.
Increased Competition
With heightened competition levels, startups that are stepping foot into popular playing fields must differentiate their products in a crowded market.
This involves refining clinical trial strategies, enhancing patient outcomes or exploring new pricing models.
The Pressure to Innovate
Only those startups that can demonstrate superior efficiency without compromising on safety and affordability will survive this race.
With competition, arises the demand for constant innovation and creative outlooks.
Market Dynamics
With newer systems hitting the market, there will be a shift in the market dynamics.
Regulatory controls now become the hurdle that needs to be bypassed which will likely help them gain an early-mover advantage.
Strategic Collaborations
Collaborations, including mergers and acquisitions, might be a common option for companies seeking resources to consolidate their resources.
This would easily mitigate the risks of overcrowding and would place your company at strategic advantage to level the field of play.
Platform-based Innovation
Instead of chasing a single molecule, developing drug discovery platforms and generate multiple candidates across different indications.
This helps to spread risks and make their R&D investment more scalable. Similar to Bugworks Research who uses a proprietary platform to develop novel antibiotic and immuno-oncology treatments, it can reduce duplication of effort.
AI-Powered Discovery
Generative AI and machine learning can be catalystic in pre-clinical trials. They can help identify drug candidates, predict toxicity and even model biological systems.
AI can reduce early-stage discovery costs by up to 40 per cent and improve the hit rate for promising candidates.
Companies like Qure.ai, although originally focused on radiology, is now collaborating on AI models for diagnostic aid in clinical trials.
This has significantly reduced time in patient enrolment and trial matching.
Focus on Orphan Drugs
ReaGene Innovations is exploring orphan drug development for rare autoimmune conditions, thus gaining fast-track attention from regulators and lower competition for trials.
By targeting rare diseases with smaller, underserved markets, startups can gain regulatory incentives. This can include tax benefits, market exclusivity and fast track status.
The age of billion-dollar R&D pipelines is fading, with a paradigm shift into lean pharma startups.
Smaller teams, sharper technology, and only strategic movements.
With variables like these, such startups can reinvent the pharma world and create innovations in the industry like never before.
As a building pharma startup, you need to realize that it is not always about outspending your fellow competitors; sometimes, it is about outsmarting them.
Edited by Harshajit Sarmah
